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Approximately one-third of the human proteome is made up of proteins that are entirely disordered or that
contain extended disordered regions. Although these disordered proteins are closely linked with many major
diseases, their binding mechanisms with small molecules remain poorly understood, and a major concern
is whether their specificity can be sufficient for drug development. Here, by studying the interaction of a
small molecule and a disordered peptide from the oncogene protein c-Myc, we describe a “specific-diffuse”
binding mechanism that exhibits sequence specificity despite being of entropic nature. By combining NMR
spectroscopy, biophysical measurements, statistical inference, and molecular simulations, we provide a
quantitative measure of such sequence specificity and compare it to the case of the interaction of urea, which
is diffuse but not specific. To investigate whether this type of binding can generally modify intermolecular
interactions, we show that it leads to an inhibition of the aggregation of the peptide. These results suggest that
the binding mechanism that we report may create novel opportunities to discover drugs that target disordered
proteins in their monomeric states in a specific manner.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Disordered proteins [1–8] represent a major un-
tapped potential for drug discovery [9–12]. The
identification of small molecules that interact with
the monomeric forms of these proteins, however, is
hindered by a limited understanding of the correspond-
ingmechanismsof bindingandby theuncertainty about
whether specificity is possible for these interactions.
Traditional drug discovery methods, which have been
developed mainly to target globular proteins, focus on
the optimization of interactions between small mole-
cules and binding pockets with well-defined structures
[13,14]. Disordered proteins do not readily lend
themselves to this type of binding [1–7,9–12,15,16] as
they lack stable conformations and are better
represented as ensembles of many structures with
relatively low populations. Consequently, disordered
proteins often do not adopt suitable binding pockets
amenable to traditional drug discovery programs.
Therefore, developing a greater understanding of theuthors. Published by Elsevier Ltd. This is an
rg/licenses/by/4.0/).mechanisms by which small molecules can interact
with disordered proteins, and hence potentially alter
their disease-promoting behavior, could have profound
implications for the search of new drugs. However, the
identification of small molecules that interact with
disordered proteins is particularly challenging because
their highly dynamic nature makes it extremely difficult
to study them experimentally [17], and notably, few
monomeric disorderedproteins havebeen successfully
targeted by small molecules [9–12,16–20].
In order to investigate how small molecules bind
disordered proteins, here we characterized the inter-
action between a small molecule and the disordered
protein, c-Myc. High-throughput screening ap-
proaches have already yielded several compounds
able to prevent the oncogenic dimerization of c-Myc to
its partner Max, identifying in particular a small
molecule, 10058-F4, that binds the 11-residue region
comprising residues 402–412 (c-Myc402–412)
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2773Small Molecule Specificity for Disordered Peptide[10,21–23]. In this study, we combined experimental
thermodynamic techniques wi th al l -a tom
NMR-restrained metadynamic metainference simula-
tions to determine how c-Myc402–412 binds 10058-F4,
revealing a “diffuse-specific” mechanism, which is
sequence-specific while being of predominantly en-
tropic nature.Thermodynamic characterization
As c-Myc402–412 is disordered, we asked whether
the binding mechanism of this monomeric peptide
to 10058-F4 could be characterized in terms of
equilibrium thermodynamics. To ensure that we were
indeedworkingwith themonomeric peptide, dynamic
light scattering measurements were taken of the
sample prior to any other measurements (Fig. S1).
Given the absence of well-defined binding pockets
within this short, disordered peptide, the identification of
a thermodynamic signature of binding is fundamental
for understanding the mechanism of this interaction.
Therefore, we performed isothermal titration calorime-
try (ITC) on this system (Fig. 1a), which is one of the
most conventional and well-established methods forFig. 1. Thermodynamic characterization of the interacti
Ac-YILSVQAEEK-NH2 (c-Myc402–412) and 10058-F4. (a) ITC
titrated into the compound solution 10058-F4 (30 μM) with corr
accounting for heats of dilution. (c) Intrinsic fluorescence titratio
the SD from three independent experiments. (d) Van't Hoff andirect, label-free measurements of enthalpic changes
[13,17]. Using this method, we detected heats of
dilution indicative of low enthalpic contributions to
the binding at 25 °C (Fig. 1b). As similar results were
obtained by repeating the experiments at 15 °C, we
were prompted to more closely consider entropic
contributions.
To unambiguously elucidate the contributions of
enthalpy and entropy in this interaction, we performed
a van't Hoff analysis (Fig. 1d) using fluorescence
titration experiments (Fig. S2) at different temperatures
(Fig. 1c), taking advantage of the intrinsic fluorescence
of a tyrosine residue within the peptide sequence, and
found consistent results with the ITC experiments.
At room temperature, we observed an affinity of 14 μM
with a 95% confidence interval (95% CI 12.2,
15.9 μM), consistent with the affinity previously report-
ed of 13 ± 1 μM [10]. This analysis showed
that the binding free energy (−27.6 ± −8.5 kJ/mol at
25 °C) predominantly comprised entropic contribu-
tions (−20.7 ± −4.2 kJ/mol), while enthalpic contribu-
tions were also observed (−7.0 ± −4.3 kJ/mol).
We thus concluded that the binding of 10058-F4 to
the disordered c-Myc peptide is associated with an
increase of entropy of the system.on between the disordered 11-residue c-Myc peptide,
binding isotherms in which c-Myc402–412 (590 μM) was
esponding heats of dilution. (b) Integrated peaks from ITC,
ns performed at various temperatures. Error bars represent
alysis of the data shown in panel c.
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To gain mechanistic insight into the specificity of
this entropic binding, we determined a structural
ensemble representing the bound (holo) state of
c-Myc402–412 and 10058-F4. To achieve this result,
we incorporated NMR measurements into molecular
dynamic simulations by performing metadynamic
metainference simulations [24,25] which combine a
physical model of the system with NMR data [26,37].
Specifically, we used previously published backbone
chemical shifts data (apo: 11 13Cα chemical shifts,
7 13Cβ chemical shifts, 11 1Hα chemical shifts, and
11 1Hbackbone amide chemical shifts; holo: 11 13Cα
chemical shifts, 4 13Cβ chemical shifts, and 11 1Hα
chemical shifts) [10]. We performed metadynamic
metainference simulations [24,25,36] with GRO-
MACS [34] equipped with PLUMED [35].
We parameterized a classical force field based on
quantum mechanical calculations for the 10058-F4
molecule (see Methods), as we found that the
Generalized Amber Force Field [27] tends to overes-
timate the potential energy barrier for dihedral rotation
between the two rings of 10058-F4 (Fig. S3, see
Methods). To ensure convergence, simulations of
c-Myc402–412 in the presence and absence of
10058-F4 were performed in duplicate for at least
5 μs each, at which point the estimated free energies
remained constant (Fig. S4) and the populations
of conformational clusters were consistent between
runs (Fig. S5). As a validation of the accuracy of
the simulations, we first computed the number of
expected nuclear overhauser effect (NOE) crosspeaks
between the small molecule and each residue within
thepeptidesequence (seeSupplementary Information)
and found good agreement with the corresponding
experimental measurements (Fig. S6) [10]. We then
computed the distribution of distances between termi-
nal Cα atoms throughout the simulation and found
close agreement with dynamic light scattering mea-
surements of the c-Myc402–412 peptide (Fig. S7). The
ability to predict multiple independent observables
suggests that the metadynamic metainference sim-
ulations rather accurately represent the conforma-
tional ensemble of c-Myc402–412.
The results of the metadynamic metainference
simulations suggest that this binding is diffuse, or
“fuzzy” [28], as c-Myc402–412 remains disordered and
10058-F4 is delocalized across several residues of
the peptide, consistent with previous simulations of
this interaction and those of other small molecules
identified to bind c-Myc (Fig. 2) [22,29].Sequence specificity
To probe the sequence specificity of this entropic
interaction, we directly compared the simulations
described above with additional metadynamicssimulations of c-Myc402–412 in the presence of
urea, which is known to interact promiscuously with
proteins (Fig. 2). Comparison of the results of these
two sets of simulations suggests that while both
10058-F4 and urea bind to c-Myc402–412 in a
delocalized manner, 10058-F4 exhibits notable se-
quence specificity, which results in a preference for
the hydrophobic N-terminus of the peptide (Fig. 2a, b)
and large differences in residue-dependent side
chain versus backbone contacts in bound confor-
mations (Fig. 2c). In contrast, urea interacts with
each residue with a more homogenous manner
(Fig. 2b, d), while the preference of side chain versus
backbone contacts is largely independent of residue
type (Fig. 2f).
To quantify sequence specificity, we defined a
quantitative, residue-specific measure of specificity,
k
∼
i (see Supplementary Information). This value is not a
measure of affinity to each single amino acid alone
within the sequence, but rather ofmeasure of specificity
within the context of its neighboring residues. Large
differences in the value of k
∼
i between residues in the
case of 10058-F4 (σ=54%) characterize the degree of
sequence specificity of this interaction (Fig. 3a). To
establish a reference value for this measure of
specificity, we calculated it in the case of urea, finding
a much smaller value (σ=9%;Fig. 3a, inset).
In addition to this distance-based measure of
specificity, we also measured sequence specificity
using a Voronoi volume approach (see Supplementary
Information), which quantifies the probability of a
given residue being involved in binding in terms of the
number of small-molecule atoms with which it exclu-
sively interacts (10058-F4: Fig. 3b, urea: Fig. S8). For
example, residue Y402 interacts with 10058-F4
in 30.8% of the bound conformations, involving side
chains in the majority of cases (87.5%). The three
residueswith thehighest probabilities of interactingwith
10058-F4 are Y402, Q407, and L404. Interestingly, Q407
and L404 are the two point mutations that were
previously reported to impair the binding [10], thus
providing further validation to our simulations.While the
two measures of sequence specificity proposed here
yield complementary information, they both demon-
strated that the binding is diffuse along the c-Myc402–412
sequence,with preferential binding to specific residues.Mutagenesis studies to validate
the simulations
Our analysis identified Q407 and L404 as important
residues for binding. These point mutations along
with V406A and E409V were previously reported
to impair binding of the basic-helix–loop–helix–
leucine–zipper (residues 351–439), which encom-
passes c-Myc402–412, to 10058-F4 [10]. As such, we
performed fluorescence quenching experiments of
the same mutants within c-Myc402–412 and observed
Fig. 2. Characterization of sequence specificity in the binding of 10058-F4 to c-Myc402–412. A structural ensemble that
illustrates the mechanism of “specific-diffuse binding” for 10058-F4 (a) and urea (b). The statistical weights of different
bound conformations are illustrated by varying opacity. Radial distribution function p(r) between 10058-F4 (c) or urea
(d) and each residue of c-Myc402–412. The inset on panel d shows the same plot on a different scale. Fractions of side
chain versus backbone contacts for bound conformations (rb 0.75 nm) for each residue in the case of 10058-F4 (e) and
urea (f). The purple bars are placed at the minimum and maximum values of the fraction of contacts across all residues.
2775Small Molecule Specificity for Disordered Peptidethat the binding of 10058-F4 is modestly weakened
by these mutations (L404P = 15.8 μM, 95% CI [14.3,
17.4 μM]; Q407K = 16.7 μM, 95% CI [16.3, 17.2 μM];
and V406A-E409V = 20.7 μM, 95%CI [20.0, 21.4 μM];
Fig. S9). These results suggest a lower cooperativity
in the binding of 10058-F4 with the c-Myc402–412
variants, which may reflect a less diffuse binding.
These experiments not only validate our simulations
but also the use of the 11-residue model to represent
the full basic-helix–loop–helix–leucine–zipper region,as our ranking of these affinities is consistent with the
previously reported changes in fluorescence polari-
zation of the full zipper region [10].Analysis of the nature of
10058-F4/c-Myc402–412 interaction
We investigated the physico-chemical origin of this
“specific-diffuse” mechanism by characterizing
Fig. 3. Quantification of the sequence
specificity in the binding of 10058-F4 to
c-Myc402–412. (a) A measure of specificity
( k
∼
i ) for each residue i with 10058-F4
(black) and urea (white). The inset shows
the relative SD (σ) ofk
∼
i computed over all
the residues for 10058-F4 and urea.
(b) Voronoi analysis showing the proba-
bility of a given residue interacting with
10058-F4. Results are weighted based
on the number of atoms within 10058-F4
with which each residue interacts. Solid
colors indicate fraction of side chain
interactions, whereas faded colors indi-
cate backbone interactions. (c) Struc-
tures i l lus t ra te the in te ract ions
underlying this specificity, including π–π
stacking between the phenyl rings of
10058-F4 and the terminal tyrosine,
hydrophobic interactions, hydrogen
bonding and electrostatic interactions,
among others.
2776 Small Molecule Specificity for Disordered Peptideentropic and enthalpic contributions to the binding.
We first quantified the change in conformational
entropy of c-Myc402–412 upon binding to the small
molecule (see Supplementary Information). Since
we could not observe a significant change in the
conformational entropy of the peptide, our results
suggest that the main source of entropy observed
experimentally is likely due to the release of water
molecules. We then analyzed possible enthalpic
contributions to the binding (see Supplementary
Information). While strong electrostatic interactions
were observed for the charged C-terminal region,
we did not observe such interactions to the
N-terminus, suggesting that the predominant
binding to this region is driven by hydrophobicity
(Fig. S10).Modulation of the behavior of c-Myc402-412
upon binding 10058-F4
While it has been shown that 10058-F4 is
effective in inhibiting the cancer-promoting dimer-
ization of c-Myc to its partner Max [9,23], we asked
whether or not this sequence-specific, delocalized,
entropic binding could be a general strategy to
modulate protein behavior. Using protein aggre-
gation as a model of protein behavior [30], we
tested the efficacy of 15 μM 10058-F4 on the
aggregation of 50 μM of the c-Myc402–412 peptide,
monitored by 8-Anilinonaphthalene-1-sulfonic acid
fluorescence. We observed that the presence of
the compound slows down aggregation and
changes the morphology of c-Myc aggregates
Fig. 4. The small molecule 10058-F4 inhibits the
aggregation of the c-Myc peptide. (a) Kinetic profile of
c-Myc402–412 (50 μM) aggregation in the presence (red)
and absence (black) of 15 μM 10058-F4 monitored by
ANS fluorescence. Dashed lines represent standard error.
(b) Structural characterization of aggregates using trans-
mission electron microscopy. The coloring schemes are
the same as in panel a.
2777Small Molecule Specificity for Disordered Peptide(Fig. 4). These results provide initial evidence that
targeting the monomeric states of disordered
proteins via entropic binding may lead to the
development of therapeutic strategies to modify
the behavior of these proteins, including those
involved in cancer [9,31] and in neurodegenera-
tion [30,32].Concluding remarks
The high prevalence of disordered proteins in
human disease makes them ideal drug targets, yet
a poor understanding of their binding mechanisms
with small molecules has largely prevented the
development of small molecules capable of altering
the disease-promoting behavior of these proteins.
Specifically, drug development efforts targeting
disordered proteins are hindered by concerns
about specificity, as many of the small molecules
identified to bind disordered regions have general
promiscuity toward other proteins. Despite evi-
dence that its binding is localized to the
11-residue region within the c-Myc protein [10],
10058-F4, like many of the other c-Myc binders,
contains a benzylidene rhodanine scaffold, which
binds a wide range of diverse biomolecules [33].However, since 10058-F4 does exhibit sequence
specificity toward this peptide, a quantitative,
structural understanding of this property may offer
novel insights for the development of molecules
capable of binding disordered proteins into viable
therapeutics. In this study, we have shown that a
small molecule can bind to a disordered peptide via
an entropically driven process, which is diffuse and
yet shows sequence specificity. To achieve this
result, we exploited metainference metadynamics,
an integrative technique that combines experimen-
tal data with the power of simulations to generate a
quantitative, all-atom structural understanding of
this specificity [26].
On thebasis of these results, we anticipate thatmore
small molecules will be discovered that are capable of
modulating the disease-promoting behavior of disor-
dered proteins and that detailed analyses of their
mechanisms of interaction will facilitate the under-
standing of the factors that canbeexploited to increase
their specificity.Acknowledgments
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